Asterasis, a corporation specializing in aesthetic medical devices, has gathered more than 3.7 trillion won in deposits for its public offering aimed at general investors.
According to the investment banking (IB) industry on the 15th, the comprehensive competition rate for Asterasis, which conducted general subscription for two days from the previous day, was recorded at approximately 1,791 to 1. The number of subscriptions was 87,593, and the subscription deposit, in which half of the order amount is paid in advance, amounted to 3.76 trillion won.
The number of shares distributed equally to subscribers was approximately 5.2 shares. Investors who subscribed for at least the minimum unit (20 shares) will receive 5 shares and have about a 20% chance of being allocated one additional share. Asterasis is set to be listed on KOSDAQ on the 24th. The underwriter is DB Financial Investment.
Earlier, Asterasis confirmed the offering price at the upper end of the desired price range (4,000 to 4,600 won) at 4,600 won based on the results of the demand forecast for institutional investors. A total of 2,219 domestic and foreign institutions participated in the demand forecast, recording a competition rate of 1,242 to 1, with the ratio of orders placed at prices higher than the upper limit being 20.99% based on the number of applications. The mandatory holding commitment accounted for 9.98% of the total participation volume.
The company, established in 2015, specializes in the manufacturing and sales of aesthetic medical devices. Its flagship product, the high-intensity focused ultrasound (HIFU) device "Lifttera," has generated cumulative sales of 18.1 billion won by the third quarter of last year. Operating profit was recorded at 3 billion won, and net profit stood at 1.7 billion won.